JP2019518798A - リポヌクレオチドに基づくardsの治療 - Google Patents
リポヌクレオチドに基づくardsの治療 Download PDFInfo
- Publication number
- JP2019518798A JP2019518798A JP2019519626A JP2019519626A JP2019518798A JP 2019518798 A JP2019518798 A JP 2019518798A JP 2019519626 A JP2019519626 A JP 2019519626A JP 2019519626 A JP2019519626 A JP 2019519626A JP 2019518798 A JP2019518798 A JP 2019518798A
- Authority
- JP
- Japan
- Prior art keywords
- cdp
- composition
- choline
- ards
- dag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355096P | 2016-06-27 | 2016-06-27 | |
| US62/355,096 | 2016-06-27 | ||
| PCT/US2017/039545 WO2018005527A1 (en) | 2016-06-27 | 2017-06-27 | Liponucleotide-based therapy for ards |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518798A true JP2019518798A (ja) | 2019-07-04 |
| JP2019518798A5 JP2019518798A5 (https=) | 2020-08-06 |
Family
ID=60786443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519626A Pending JP2019518798A (ja) | 2016-06-27 | 2017-06-27 | リポヌクレオチドに基づくardsの治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10874684B2 (https=) |
| EP (2) | EP4292651A3 (https=) |
| JP (1) | JP2019518798A (https=) |
| KR (1) | KR20190022682A (https=) |
| CN (1) | CN109475554A (https=) |
| AU (1) | AU2017289278A1 (https=) |
| CA (1) | CA3029005A1 (https=) |
| SG (1) | SG11201811595SA (https=) |
| WO (1) | WO2018005527A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201811595SA (en) * | 2016-06-27 | 2019-01-30 | Ohio State Innovation Foundation | Liponucleotide-based therapy for ards |
| US11154621B2 (en) | 2017-06-27 | 2021-10-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for COPD |
| EP4125857A4 (en) * | 2020-03-31 | 2024-04-17 | Diffusion Pharmaceuticals LLC | USE OF DIFFUSION ENHANCEMENT COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASE INDUCED BY VIRUSES AND BACTERIA |
| WO2021222535A1 (en) * | 2020-05-01 | 2021-11-04 | Irazu Bio | Method for treating respiratory viral infections comprising administration of fatty acid compositions |
| US20250177541A1 (en) * | 2022-03-11 | 2025-06-05 | Arizona Board Of Regents On Behalf Of Arizona State University | Pegylated serp-1 protein treatment improves outcomes after sars-cov-2 infection |
| US20250170246A1 (en) * | 2022-03-18 | 2025-05-29 | Ohio State Innovation Foundation | Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
| JPH02500372A (ja) * | 1987-10-28 | 1990-02-08 | プロ‐ニューロン,インコーポレーテッド | アシル化ウリジンおよびシチジンならびにその使用 |
| US20030181353A1 (en) * | 1998-08-03 | 2003-09-25 | Nyce Jonathan W. | Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia |
| JP2005513023A (ja) * | 2001-11-21 | 2005-05-12 | ダンマークス・ヨードブルースフォースクニング | 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用 |
| JP2008542280A (ja) * | 2005-05-23 | 2008-11-27 | マサチューセッツ・インスティチュート・オブ・テクノロジー | Pufa及び/又はウリジンを含有する組成物及びそれを使用した方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| JP4408450B2 (ja) * | 1994-07-01 | 2010-02-03 | ウェルスタット セラピューティクス コーポレイション | 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体 |
| US6825174B2 (en) * | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
| US20040049022A1 (en) * | 2001-04-24 | 2004-03-11 | Nyce Jonathan W. | Composition & methods for treatment and screening |
| EP2329826A1 (en) * | 2001-07-13 | 2011-06-08 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of multiple sclerosis |
| CA2587883A1 (en) * | 2004-11-17 | 2006-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma |
| CN101495490B (zh) * | 2005-05-23 | 2018-05-08 | 麻省理工学院 | 含有多不饱和脂肪酸和/或尿苷的组合物及其使用方法 |
| SG11201811595SA (en) * | 2016-06-27 | 2019-01-30 | Ohio State Innovation Foundation | Liponucleotide-based therapy for ards |
| US11154621B2 (en) * | 2017-06-27 | 2021-10-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for COPD |
| US11850283B2 (en) * | 2017-06-27 | 2023-12-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for asthma |
-
2017
- 2017-06-27 SG SG11201811595SA patent/SG11201811595SA/en unknown
- 2017-06-27 EP EP23207788.3A patent/EP4292651A3/en active Pending
- 2017-06-27 JP JP2019519626A patent/JP2019518798A/ja active Pending
- 2017-06-27 WO PCT/US2017/039545 patent/WO2018005527A1/en not_active Ceased
- 2017-06-27 EP EP17821089.4A patent/EP3474853A4/en not_active Withdrawn
- 2017-06-27 CN CN201780039385.4A patent/CN109475554A/zh active Pending
- 2017-06-27 AU AU2017289278A patent/AU2017289278A1/en not_active Abandoned
- 2017-06-27 KR KR1020197002042A patent/KR20190022682A/ko not_active Ceased
- 2017-06-27 CA CA3029005A patent/CA3029005A1/en active Pending
-
2018
- 2018-12-21 US US16/230,225 patent/US10874684B2/en active Active
-
2020
- 2020-11-19 US US16/952,557 patent/US20210069225A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
| JPH02500372A (ja) * | 1987-10-28 | 1990-02-08 | プロ‐ニューロン,インコーポレーテッド | アシル化ウリジンおよびシチジンならびにその使用 |
| US20030181353A1 (en) * | 1998-08-03 | 2003-09-25 | Nyce Jonathan W. | Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia |
| JP2005513023A (ja) * | 2001-11-21 | 2005-05-12 | ダンマークス・ヨードブルースフォースクニング | 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用 |
| JP2008542280A (ja) * | 2005-05-23 | 2008-11-27 | マサチューセッツ・インスティチュート・オブ・テクノロジー | Pufa及び/又はウリジンを含有する組成物及びそれを使用した方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4292651A2 (en) | 2023-12-20 |
| US20210069225A1 (en) | 2021-03-11 |
| KR20190022682A (ko) | 2019-03-06 |
| SG11201811595SA (en) | 2019-01-30 |
| EP4292651A3 (en) | 2024-03-13 |
| CA3029005A1 (en) | 2018-01-04 |
| US10874684B2 (en) | 2020-12-29 |
| EP3474853A1 (en) | 2019-05-01 |
| AU2017289278A1 (en) | 2019-01-17 |
| EP3474853A4 (en) | 2020-02-19 |
| WO2018005527A1 (en) | 2018-01-04 |
| US20190134074A1 (en) | 2019-05-09 |
| CN109475554A (zh) | 2019-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518798A (ja) | リポヌクレオチドに基づくardsの治療 | |
| US20240245646A1 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
| JP2016516773A5 (https=) | ||
| US20170354711A1 (en) | High density lipoprotein nanoparticles for inflammation | |
| JP2001520656A (ja) | 抗腫瘍剤としてのホルボールエステル類 | |
| JP2016121188A (ja) | 肝細胞がんの予防及び/又は治療のための医薬 | |
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| TW202203946A (zh) | 用於人或動物之慢性或急性之病毒感染症及/或敗血症之預防或治療的組成物 | |
| JP2013510838A (ja) | 微生物感染症の治療 | |
| HK40003888A (en) | Liponucleotide-based therapy for ards | |
| JP2004504346A (ja) | 骨転移の治療におけるリン酸エストラムスチンの使用 | |
| EP4104825A1 (en) | Pharmaceutical composition for inhibiting inflammatory response comprising hydroxyurea | |
| US20250170246A1 (en) | Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection | |
| CN112533605A (zh) | 用于治疗癌症的组合疗法 | |
| JP2017527567A5 (https=) | ||
| JP2013126971A (ja) | 抗感冒剤 | |
| Chou et al. | Rapid development of severe skin rash after adding valproic acid in a case of bipolar depression treated with low-dose lamotrigine | |
| CN112533604A (zh) | 用于治疗癌症的组合疗法 | |
| JP6959049B2 (ja) | 新規低アルブミン血症改善薬 | |
| JP2019503344A (ja) | 細菌感染を治療する新規方法 | |
| CN1739543A (zh) | 抗肿瘤化合物nobilisideA单乙酰化物脂质体静脉注射液及其制法 | |
| WO2022121884A1 (zh) | 伊维菌素及其类似物在皮肤相关疾病治疗中的应用 | |
| WO2013008681A1 (ja) | 線維症予防又は治療用医薬組成物 | |
| BR112018012195B1 (pt) | Uso de 2-[4-(1,1-dimetiletil)fenil]-1h-benzimidazol, ou um sal farmaceuticamente aceitável do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200626 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200626 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210706 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220208 |